October 13, 2010 (Liege, Belgium) — In patients with treatment-resistant, active acromegaly, normalizing insulin-like growth factor 1 (IGF-1) levels leads to a marked reduction in cardiovascular risk, ...

Acromegaly affects more than just your physical health. Learn how to manage the psychological impact of appearance changes and diagnostic delays, and how to find a supportive community.

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

Acromegaly can lead to serious health issues like heart disease and diabetes if left unmanaged. Learn how to prevent complications through treatment and lifestyle changes.

Paltusotine is the first once-daily oral therapy approved for acromegaly, offering a non-invasive alternative to injections. PATHFNDR-1 and PATHFNDR-2 trials showed significant efficacy in IGF-1 ...

A daily oral therapy reduced insulin-like growth factor I levels and improved symptoms in a real-world setting among adults ...

Please provide your email address to receive an email when new articles are posted on . “It is well known that insulin-like growth factor I has mitogenic and antiapoptotic activity,” Muhammed Kizilgul ...

Crinetics Pharmaceuticals, Inc. is my latest long position. The company has two Phase 3 data releases for Paltusotine in treating acromegaly over the next 7-8 months. Acromegaly is a disorder caused ...

LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

The journal Pituitary has highlighted research led by Manel Puig, head of the Endocrine, Thyroid and Obesity Research Group at the Germans Trias i Pujol Research Institute (IGTP), which explores the ...